Riad, Saudi-Arabien (ots/PRNewswire)
- MS Pharma opens the first production facility in the Middle East in Saudi Arabia for biologicals approved by the SFDA and corresponds to the standards of the EMA and FDA.
- Specialized in monoclonal antibodies and complex peptideswith your own bioanalytic laboratories.
- Strategic platform for global partnerswhich enables localized production and contract manufacturing for access to the markets in the Middle East, North Africa, the EU and the USA.
MS Pharma officially inaugurated the first production facility for biologicals in the Middle East, which is strategically cheap to Saudi Arabia. The system has received the approval in accordance with the principles of good manufacturing practice (“Good Manufacturing Practice”, GMP) from the Saudi food and drug authority (“Saudi Food and Drug Authority”, SFDA) and thus forms a hub for the advanced biopharmaceutical production in the MENA region.
With capacities in the areas of formulation, bottling and lyophilization, this investment of $ 50 million MS Pharma positions as the leading provider of biologics in the region. In addition, it establishes the company as a reliable partner for global pharmaceutical companies who are looking for access to the Saudi market and the Mena region via local manufacturing and wage manufacturing solutions for broader international markets.
According to the highest international regulatory standards, including EMA and US FDA, the system was designed and specializes in monoclonal antibodies and complex peptides-two of the most sought-after biological treatment classes. The system also has the region’s first internal bioanalytic test laboratories, which means that test services abroad are no longer required and the market launch of critical treatments is accelerated.
“This market launch is a decisive milestone for MS Pharma and the biopharmaceutical landscape in the Middle East and North Africa,” said Ghiath Sukhtian, CEO of MS Pharma. “We are proud to promote a regional platform for biologicals that meet the global requirements in the healthcare system and, in cooperation with international partners, provide high -quality, complex medication.”
Kalle Känd, Managing Director of MS Pharma, added: “This system is more than just a facility for manufacturing – it is a strategic pioneer for global partnerships that offers regional access and wage manufacturing capacities for international markets. In addition, it opens up localization incentives and strengthens our contribution to national and regional goals in relation to local content, highly qualified employment and technology transfer.”
In accordance with the localization goals and the Vision 2030 Saudi Arabia, the system in Riyadh uses industrial incentives and its strategically favorable location to operate the kingdom, the Mena region and the export markets in the EU and the USA. MS Pharma thus strengthens its role as a regional market leader in the field of biologicals with the skills, capacities and compliance standards to operate various markets and increase its value as a production and partnership platform.
Information on MS Pharma
MS Pharma is a leading multinational pharmaceutical company that works for access to high -quality medication in the Middle East, in Africa and beyond. The company was founded in Amman, Jordan, in 1989 and employed over 2,000 people in twelve countries. It operates five production facilities in Jordan, Algeria and Saudi Arabia. MS Pharma’s portfolio includes the development, manufacture and distribution of generics, complex injection products and biosimilars to treat a variety of therapy areas, including oncology, cardiovascular diseases and disorders of the central nervous system. The company thus contributes to better health results in the entire region.
Further information:
Video – https://mma.prnewswire.com/media/2759181/MS_Pharma_Biologics.mp4
Photo – https://mma.prnewswire.com/media/2759178/MS_Pharma_Saudi_Arabia.jpg
Logo – https://mma.prnewswire.com/media/2759179/MS_Pharma_Logo.jpg
